Skip to content
← Juvenile Myelomonocytic Leukemia

HEALTH PROFESSIONAL · SOURCE READING

Treatment Options Under Clinical Evaluation

Source: Juvenile Myelomonocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 10, 2024 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Source links and citations

The following is an example of a national and/or institutional clinical trial that is currently being conducted:

NCT05849662 (A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia [JMML]): This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with JMML.

Source links and citations

Studies cited in this source section

Source citation is not a determination that a study applies to you.

Preserved source evidence · Not medical advice